Stadler WM - Search Results

1

Development of target-based antineoplastic agents.

Stadler WM, Ratain MJ. Stadler WM, et al. Invest New Drugs. 2000 Feb;18(1):7-16. doi: 10.1023/a:1006371512390. Invest New Drugs. 2000. PMID: 10830137 Review.

2

Granulocyte-macrophage--colony stimulating factor in metastatic renal cell carcinoma: a phase II trial.

Rini BI, Stadler WM, Spielberger RT, Ratain MJ, Vogelzang NJ. Rini BI, et al. Among authors: stadler wm. Cancer. 1998 Apr 1;82(7):1352-8. doi: 10.1002/(sici)1097-0142(19980401)82:7<1352::aid-cncr19>3.0.co;2-5. Cancer. 1998. PMID: 9529028 Clinical Trial.

3

Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer.

Vogelzang NJ, Mani S, Schilsky RL, Ansari RH, Taber D, Rhinehart SN, Garcia JC, Meyer SC, Mick R, Brockstein BE, Stadler WM, Ratain MJ, Vokes EE. Vogelzang NJ, et al. Among authors: stadler wm. Clin Cancer Res. 1998 Apr;4(4):929-34. Clin Cancer Res. 1998. PMID: 9563886 Clinical Trial.

4

Study of cohort-specific consent and patient control in phase I cancer trials.

Daugherty CK, Ratain MJ, Minami H, Banik DM, Vogelzang NJ, Stadler WM, Siegler M. Daugherty CK, et al. Among authors: stadler wm. J Clin Oncol. 1998 Jul;16(7):2305-12. doi: 10.1200/JCO.1998.16.7.2305. J Clin Oncol. 1998. PMID: 9667244 Clinical Trial.

5

Development of a schedule-dependent population pharmacodynamic model for rhizoxin without quantitation of plasma concentrations.

Goh BC, Fleming GF, Janisch L, Vogelzang NJ, Stadler WM, Ratain MJ. Goh BC, et al. Among authors: stadler wm. Cancer Chemother Pharmacol. 2000;45(6):489-94. doi: 10.1007/s002800051024. Cancer Chemother Pharmacol. 2000. PMID: 10854137 Clinical Trial.

6

Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea.

Innocenti F, Stadler WM, Iyer L, Ramírez J, Vokes EE, Ratain MJ. Innocenti F, et al. Among authors: stadler wm. Clin Cancer Res. 2000 Sep;6(9):3400-5. Clin Cancer Res. 2000. PMID: 10999721

7

Angiogenesis inhibitors.

Tennant TR, Rinker-Schaeffer CW, Stadler WM. Tennant TR, et al. Among authors: stadler wm. Curr Oncol Rep. 2000 Jan;2(1):11-6. doi: 10.1007/s11912-000-0005-0. Curr Oncol Rep. 2000. PMID: 11122819 Review.

8

Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.

Rudin CM, Holmlund J, Fleming GF, Mani S, Stadler WM, Schumm P, Monia BP, Johnston JF, Geary R, Yu RZ, Kwoh TJ, Dorr FA, Ratain MJ. Rudin CM, et al. Among authors: stadler wm. Clin Cancer Res. 2001 May;7(5):1214-20. Clin Cancer Res. 2001. PMID: 11350886 Clinical Trial.

9

Clinical trial designs for cytostatic agents.

Ratain MJ, Stadler WM. Ratain MJ, et al. Among authors: stadler wm. J Clin Oncol. 2001 Jun 15;19(12):3154-5. doi: 10.1200/JCO.2001.19.12.3154. J Clin Oncol. 2001. PMID: 11408513 No abstract available.

10

A phase II trial of weekly intravenous ranpirnase (Onconase), a novel ribonuclease in patients with metastatic kidney cancer.

Vogelzang NJ, Aklilu M, Stadler WM, Dumas MC, Mikulski SM. Vogelzang NJ, et al. Among authors: stadler wm. Invest New Drugs. 2001;19(3):255-60. doi: 10.1023/a:1010633004157. Invest New Drugs. 2001. PMID: 11561684 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

343 results

Search Page

Filters